Several ongoing clinical trials are evaluating the efficacy of the FAK inhibitor defactinib (VS-6063) in combination with radiotherapy (stereotactic body radiotherapy, NCT04331041), or immunotherapy (αPD-1 antibody pembrolizumab, NCT02758587, and NCT03727880) for pancreatic cancer treatment. Here, PTK2 is linked to familial pancreatic carcinoma.